4.8 Article

Cascade-Targeting Poly(amino acid) Nanoparticles Eliminate Intracellular Bacteria via On-Site Antibiotic Delivery

Journal

ADVANCED MATERIALS
Volume 34, Issue 12, Pages -

Publisher

WILEY-V C H VERLAG GMBH
DOI: 10.1002/adma.202109789

Keywords

cascade-targeting drug delivery systems; intracellular bacteria targeting; macrophage polarization; on-site antibiotic delivery; poly(N-acryloyl amino acid)

Funding

  1. National Natural Science Foundation [21574008, 22005020]
  2. National Mega-project for Innovative Drugs [2019ZX09721001-007-002]
  3. Key Program of Beijing Natural Science Foundation [Z200025]
  4. Fundamental Research Funds for the Central Universities of China [BHYC1705B]

Ask authors/readers for more resources

A cascade-targeting drug delivery system has been developed to sequentially target macrophages and intracellular bacteria, allowing on-site drug delivery. The system encapsulates rifampicin into mannose-decorated nanoparticles, which are designed to specifically target macrophages and then release the drug in acidic environments to effectively eliminate intracellular bacteria. The system also modulates the innate immune response of infected macrophages, enhancing antibacterial capacity.
Intracellular bacteria in latent or dormant states tolerate high-dose antibiotics. Fighting against these opportunistic bacteria has been a long-standing challenge. Herein, the design of a cascade-targeting drug delivery system (DDS) that can sequentially target macrophages and intracellular bacteria, exhibiting on-site drug delivery, is reported. The DDS is fabricated by encapsulating rifampicin (Rif) into mannose-decorated poly(alpha-N-acryloyl-phenylalanine)-block-poly(beta-N-acryloyl-d-aminoalanine) nanoparticles, denoted as Rif@FAM NPs. The mannose units on Rif@FAM NPs guide the initial macrophage-specific uptake and intracellular accumulation. After the uptake, the detachment of mannose in acidic phagolysosome via Schiff base cleavage exposes the d-aminoalanine moieties, which subsequently steer the NPs to escape from lysosomes and target intracellular bacteria through peptidoglycan-specific binding, as evidenced by the in situ/ex situ co-localization using confocal, flow cytometry, and transmission electron microscopy. Through the on-site Rif delivery, Rif@FAM NPs show superior in vitro and in vivo elimination efficiency than the control groups of free Rif or the DDSs lacking the macrophages- or bacteria-targeting moieties. Furthermore, Rif@FAM NPs remodel the innate immune response of the infected macrophages by upregulating M1/M2 polarization, resulting in a reinforced antibacterial capacity. Therefore, this biocompatible DDS enabling macrophages and bacteria targeting in a cascade manner provides a new outlook for the therapy of intracellular pathogen infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available